{
  "id": 723278,
  "title": "AI is not the beginning of drug discovery — it is the accelerator",
  "url": "https://urgent.news/2026/08/13/ai-is-not-the-beginning-of-drug-discovery-it-is-the-accelerator",
  "topic": "ai",
  "section": "AI",
  "published": "2026-08-13T02:30:46.000Z",
  "source": {
    "name": "e27",
    "slug": "e27",
    "url": "https://e27.co/ai-is-not-the-beginning-of-drug-discovery-it-is-the-accelerator-20260812/"
  },
  "original_language": "en",
  "account": "Artificial intelligence is not a new technology in drug discovery; it has been part of pharmaceutical research for decades. Computational drug discovery methods, such as molecular docking, QSAR models, pharmacokinetic simulations, and virtual screening, have been used since the 1990s. This foundation exists because AI has been amplifying rather than replacing computational chemistry. Traditional methods were limited by human bandwidth, but AI can analyze millions of chemical structures, identify hidden relationships, predict molecular properties, and improve as more data becomes available. This allows researchers to spend less time searching and more time validating the most promising candidates. This shift is already happening at companies like Isomorphic Labs, Insilico Medicine, Recursion, and NVIDIA. Effective partnerships between pharmaceutical companies and AI firms are crucial, as each brings unique expertise to the table. While hospitals are slower to adopt AI due to regulatory concerns and workflow complexity, the technology's impact on drug discovery is undeniable. The future of AI in pharmaceuticals is about accelerating existing methods rather than starting from scratch.",
  "summary": "Artificial intelligence is often framed as the technology that suddenly changed drug discovery. But that narrative misses an important truth: computational, or in silico, drug discovery did not begin with AI. It has been part of pharmaceutical research for decades. Long before today’s large models and generative systems, scientists were already using molecular docking, QSAR […] The post AI is not…",
  "key_points": [
    "AI has been part of drug discovery for decades, not a new technology",
    "AI accelerates computational chemistry by analyzing vast chemical structures",
    "Effective partnerships between pharma and AI firms are crucial for progress"
  ],
  "editors_take": "Pharmaceutical companies gain from AI by accelerating existing drug discovery methods, allowing researchers to focus on validating promising candidates rather than searching for them.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}